Last update 17 Nov 2025

The United Bio-Technology(Hengqin) Co., Ltd.

Subsidiary Company|2021|Guangdong Sheng, China

Overview

Tags

Endocrinology and Metabolic Disease
Digestive System Disorders
Urogenital Diseases
Synthetic peptide
Recombinant polypeptide
Biosimilar

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Endocrinology and Metabolic Disease7
Top 5 Drug TypeCount
Biosimilar4
Recombinant polypeptide3
Hormone2
Small molecule drug1
Synthetic peptide1
Top 5 TargetCount
GLP-1R(Glucagon-like peptide 1 receptor)2
INSR(Insulin receptor)1
SOST(Sclerostin)1
GLP-1R x INSR1
GCGR x GIPR x GLP-1R1

Related

7
Drugs associated with The United Bio-Technology(Hengqin) Co., Ltd.
UBT-251
Target
GCGR x GIPR x GLP-1R
Mechanism
GCGR agonists [+2]
Active Org.
The United Laboratories International Holdings Ltd.The United Laboratories International Holdings Ltd. [+1]
Originator Org.
The United Bio-Technology(Hengqin) Co., Ltd.
Active Indication
Metabolic Dysfunction Associated Steatohepatitis [+3]
Inactive Indication-
Drug Highest PhasePhase 2
First Approval Ctry. / Loc.-
First Approval Date-
Insulin degludec/Insulin aspart(Federal Biotechnology (Zhuhai Hengqin))
Target
INSR
Mechanism
INSR agonists
Active Org.
The United Bio-Technology(Hengqin) Co., Ltd. [+1]
Originator Org.
The United Bio-Technology(Hengqin) Co., Ltd.
Active Indication
Diabetes Mellitus, Type 2
Inactive Indication-
Drug Highest PhasePhase 1
First Approval Ctry. / Loc.-
First Approval Date-
WO2024239961
Patent Mining
Target-
Mechanism-
Active Org.
The United Bio-Technology(Hengqin) Co., Ltd.
Originator Org.
The United Bio-Technology(Hengqin) Co., Ltd.
Active Indication
Endocrinology and Metabolic Disease
Inactive Indication-
Drug Highest PhaseDiscovery
First Approval Ctry. / Loc.-
First Approval Date-
17
Clinical Trials associated with The United Bio-Technology(Hengqin) Co., Ltd.
ChiCTR2500110552
/ Not yet recruitingNot ApplicableIIT
Pharmacokinetic Study of UBT251 Injection in Subjects with Normal Renal Function and Renal Insufficiency
NCT07145151
/ RecruitingPhase 2
A Phase 2, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of UBT251 Injection in Adult Patients With Metabolic Dysfunction-associated Steatohepatitis (MASH)
NCT07134335
/ Active, not recruitingPhase 2
A Phase II Clinical Study to Evaluate the Efficacy and Safety of UBT251 Injection in Obese/Overweight Chronic Kidney Disease (CKD) Population
100 Clinical Results associated with The United Bio-Technology(Hengqin) Co., Ltd.
Login to view more data
0 Patents (Medical) associated with The United Bio-Technology(Hengqin) Co., Ltd.
Login to view more data
100 Deals associated with The United Bio-Technology(Hengqin) Co., Ltd.
Login to view more data
100 Translational Medicine associated with The United Bio-Technology(Hengqin) Co., Ltd.
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 19 Nov 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Discovery
1
2
IND Approval
Phase 1
1
1
Phase 2
Phase 3
1
1
NDA/BLA
Approved
1
Login to view more data

Current Projects

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free